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Abstract 
The chemical functionalisation of glycosaminoglycans is very challenging due to their structural 
heterogeneity and polyanionic character; but as an enabling technology it promises rich rewards in 
terms of the structural and biological data it will afford. This review surveys the known methods for 
the preparation of glycosaminoglycan oligosaccharides and conditions for the selective 
functionalisation of both the reducing and non-reducing ends. The synthetic merits of each approach 
are discussed, together with the structural modification of the glycosaminoglycan oligosaccharide 
which they confer. Recent applications of this methodology are highlighted, including introduction of 
functional labels for gel mobility shift assays and NMR studies of glycosaminoglycan-protein 
complexes, and synthesis of immobilised glycosaminoglycan arrays 
 
1. Introduction 
Glycosaminoglycans (GAGs) are linear polysaccharides found almost ubiquitously on animal cell 
surfaces and within extracellular matrices.
1
 They constitute an important class of macromolecules 
that are implicated in both the structural organisation of extracellular matrices, and how cells 
interact with them, as well as in the regulation of the biological activity of morphogens, growth 
factors, cytokines, chemokines and enzymes,
2,3
 and regulation of the immune system.
4,5
 Many of 
the functions of GAGs are mediated through their interactions with proteins;
6
 which occur via 
contacts between the negatively charged groups of GAG oligosaccharides and positively charged 
amino acid side chains. As a consequence, oligosaccharides in protein-GAG complexes do not 
occupy hydrophobic pockets, but sit on the protein surface with only a few intermolecular 
contacts,
7,8
 making solution phase structure determination of these complexes very challenging. 
Despite a wealth of chemical and genetic evidence to suggest that control of the fine structure of 
GAGs including their detailed sulfation patterns is crucial for their function in vivo,
9-12
 there have 
been comparatively few studies of these interactions at the molecular level due to a lack of 
enabling chemical tools, and even fewer studies where these interactions are placed in a broader 
context as part of the emerging field of glycomics.
13 
The four basic classes of GAGs [heparin/heparan sulfate (HS), chondroitin sulfate (CS)/ dermatan 
sulfate (DS), keratan sulfate (KS) and hyaluronan (HA)] are produced by a common biosynthetic 
pathway in which the linear alternating uronic acid/hexosamine polymeric chain is extended in a 
stepwise fashion.
14
 Heparin/HS, CS and DS share a common tetrasaccharide motif that links the 
GAG chain to the protein core.
10
 Coupling of either UDP-GlcNAc [heparin/HS] or UDP-GalNAc 
[CS, DS] to the proteoglycan core, differentiates the developing GAG;
10
 this is followed by 
coupling of UDP-gluronic acid (GlcA) to the hexosamine residue [either (13) or (14) 
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dependent upon the GAG class], and polymeric chain extension from the non-reducing end.
§
 With 
the exception of HA which is unmodified, the resultant polymer is extensively modified through 
uronic acid [GlcA to iduronic acid (IdoA)] epimerisation (heparin, HS, DS), N-deacetylation 
coupled with N-sulfation (heparin, HS), and O-sulfation (all GAGs) creating heterogeneous 
structures (Figure 1).
15
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Figure 1. GAG-polysaccharide classes.
 §
 
 
Functionalisation through the attachment of fluorescent labels, spin labels, or biotinylation of 
these linear oligosaccharides might be envisaged at either the reducing or non-reducing end (or 
both) to allow the wealth of modern biophysical techniques to be applied to the determina tion of 
the GAG oligosaccharide solution conformation, and to obtaining vital information about protein -
GAG interactions. The method by which the GAG oligosaccharide sample under study has been 
prepared (Section 2) determines which is the most appropriate route to functionalisation (Section 
3). But notwithstanding which method is used, the production of functionalised GAG 
oligosaccharides poses a considerable challenge due to the polyanionic character and structural 
diversity which they display along the GAG chain. The applications of these strategies 
highlighted in Section 4 are thus notable achievements in the field. 
 
2. Sample preparation 
X-ray crystal structures, a limited number of NMR studies and molecular modelling of some GAG-
protein complexes suggest that the most common length within the GAG polymer for protein 
recognition and binding consists of four to six sugar units.
6,16
 However, these studies have invariably 
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used highly sulphated heparin-derived oligosaccharides which may mask the true specificity of 
complex formation with less sulfated species in vivo. Although some evidence suggests that charge 
density is a major component of recognition for some proteins,
5
 in others evidence points to a 
significant role for the relative placement of key recognition motifs within the GAG sequence.
17 
As a further complication, the strength of binding does not always correlate with the biological 
activity; and in some instances less sulfated species have been shown to be more active.
18
 If this 
seemingly contradictory body of data is to be reconciled, sample preparation and isolation 
methods must address sample homogeneity with respect to the length of the sugar chain as well as 
its detailed saccharidic make up. Pure, well characterised species of an appropriate degree of 
polymerisation (dp) and defined sulfation pattern are urgently needed. 
Two principal methods have been used to achieve the depolymerisation of native GAG-
polysaccharides, i.e. chemical and enzymatic cleavage (Section 2.1).
19
 Both of these methods 
have found application in the commercial preparation of low molecular weight heparins for 
clinical anticoagulative treatments.
20
 For structural and biological studies these methods may be 
used to supply microgram to milligram quantities of individual dp fractions of a GAG 
oligosaccharide which may then be further purified into their individual structural components 
(Section 2.1.3). Alternatively, sample homogeneity may be achieved by the total chemical or 
chemoenzymatic synthesis of the GAG oligosaccharide (Section 2.2), or by global chemical or 
enzymatic processing (e.g. selective desulfation) of the GAG chain (Section 2.3).  
 
2.1 Preparation of GAG oligosaccharides through depolymerisation 
2.1.1 Chemical cleavage 
The chemical depolymerisation of GAGs is frequently achieved either using nitrous acid, or by radical 
cleavage in aqueous peroxide.
21
 Cleavage of 2-amino-2-deoxy-D-glucosidic bonds by nitrous acid is 
initiated by nitrosation of the amino group of the sugar,
‡
 followed by loss of nitrogen with a ring 
contraction of the D-glucosamine residue to the 2,5-anhydro-D-mannose coupled to elimination of the 
aglycone.
22
 The 2,5-anhydro-D-mannose is thus the new reducing terminal of the oligosaccharide 
formed in this deamination reaction (Scheme 1). The terminal aldehyde functionality which results is 
ideally suited to functionalisation by reductive amination, or hydrazone formation (as discussed in 
Section 3.1), and typically shows enhanced reactivity relative to comparable reactions of an 
aldohexose.
19
 Short reaction times (typically 10 min) mean that little if any desulfation occurs along 
the GAG chain. However, the conformational changes introduced by the artificial terminal residue are 
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likely to impact upon the solution conformation and protein-binding of any GAG oligosaccharide 
probe generated in this manner. 
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Scheme 1. Nitrous acid induced depolymerisation. 
 
The other method chiefly employed in the chemical preparation of short-chain GAGs is radical 
depolymerisation, using hydrogen peroxide in the presence of a transition metal catalyst such as 
copper(II) or iron(II).
23
 Typical reaction conditions include the use of Cu(OAc)2/H2O2 at pH 7.5, 
Fenton's reagent FeSO4/H2O2 at pH 4.5, and Cu(OAc)2/H2O2 at pH 4.1.
23-25
 Depolymerisation of 
CS and DS with H2O2 in the presence of a copper(II) catalyst has been shown to result in 
structural changes which render the depolymerised material more resistant to enzymatic 
degradation.
26
 Copper(II)-catalysed depolymerisation of heparin is generally more selective than 
iron(II)-catalysed depolymerisation and tends to occur adjacent to 2-O-sulfated IdoA residues; it 
is thought that the selectivity for depolymerisation is conferred by binding of the copper(II) ion to 
the GAG-polysaccharide, and this is consistent with a reduced selectivity for attack induced by 
the more weakly binding iron(II) ion.
23
 Recent studies have shown that the SO3
-
/CO2
-
 ratio (an 
index of the total sulfate group content) of "low molecular weight" heparin obtained under 
copper(II)-catalysed depolymerisation conditions is slightly higher than that of the parent 
heparin, whilst the N-sulfate content is hardly changed at all.
25
 
Two sites for the initiation of GAG depolymerisation have been proposed: radical abstraction at 
C2 or C3 of either a uronic or glucosamine residue; or alternatively radical abstraction at the 
anomeric position (Scheme 2).
27
 A stable nitroxide radical, resulting from hydroxyl radical attack 
on N-sulfated or free amino groups, has also been observed under these conditions.
28
 Overall 
radical depolymerisation is not well suited to generating homogeneous GAG oligosaccharide 
samples because it provides both odd- and even-numbered oligomers and results in many minor 
functional group alterations especially at the reducing end.
27 
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Scheme 2. Proposed radical formation and resultant cleavage products: (a) C3 (or C2) abstraction 
followed by -scission; (b) anomeric abstraction followed by oxidation and glycosidic bond cleavage. 
 
2.1.2 Enzymatic cleavage 
Enzymatic digestion of GAGs by bacterial or fungal lyases is a well-established technique for 
their depolymerisation. These eliminase enzymes fall into three classes depending on their 
primary substrate (chondroitinase, heparinase, and hyaluronidase);
29
 which are further subdivided 
according to their sequence specificities (chondroitinase AC, B, C and ABC;
30
 and heparinase I, 
II and III
31
). Mechanistically the lyase enzyme brings about the depolymerisation of the GAG 
backbone through a -eliminative cleavage as shown in Scheme 3.29 Lyases are potentially able to 
degrade GAGs down to purely disaccharides. In reality, substrate complexity usually results in a 
preponderance of di- and tetra-saccharides (dp2-dp4),
32
 mixed with larger resistant sequences, 
dependent on the individual GAG substrate used. Controlled partial digestions can be used to 
generate more complex mixtures. After separation by size-exclusion chromatography (SEC), 
these give a range of individual size fractions, typically from dp2 to ≥dp12.33  
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Scheme 3. Proposed lyase cleavage mechanism.  
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The unsaturated uronic acid (UA) at the non-reducing terminus, which results from lyase cleavage, 
has a distinctive chromophore at 230 nm ( 5000–6000 M-1 cm-1) that may be used to monitor the 
progress of the reaction.
34
 It also provides a unique functional group handle that may prove useful for 
further chemical functionalisation of the GAG oligosaccharide. Both IdoA and GlcA give the same 
UA upon cleavage, thus important sequence information may be lost. This UA residue can exist in 
either the 
2
H1 or 
1
H2 conformation; the equilibrium between these two conformers is controlled by its 
sulfation pattern.
35
 NMR studies show that 
1
H2 is generally the favoured conformation,
36
 although 
both forms appeared in the same unit cell in a crystal structure,
37
 which indicates that they have nearly 
the same energy. Where this modified uronic acid is not required at the non-reducing terminus it is 
readily removed in the presence of mercuric salts e.g. HgCl2 or Hg(OAc)2,
38
 through an 
oxymercuration reaction which is rapidly followed by hydrolysis of the resultant hemi-ketal (Scheme 
4). 
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Scheme 4. Oxymercuration and loss of the terminal 4,5 unsaturated uronic acid residue of lyase-
cleaved GAG oligosaccharides. 
 
2.1.3 Separation of GAG oligosaccharides 
The complex mixture of oligosaccharide obtained via chemical or enzymatic cleavage requires 
separation by SEC to give GAG oligosaccharides fractions of known dp.
39
 When lyase-generated 
these are readily detected by monitoring the absorption at 230 nm (Figure 2), whilst chemically 
depolymerisaed GAG oligosaccharides might require the attachment of a functional tag (e.g. 
fluorophore) to aid this process (though carbonyl bond absorption at 206 nm is possible if running 
in a low-absorbance background). 
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Figure 2. Size separation of heparin oligosaccharides obtained by heparinase I digestion of bovine 
heparin on a Biogel P10 size exclusion column. 
 
Separation of individual components from particular size fractions of any GAG oligosaccharide 
must then be achieved. The structural similarities of individual components (which may vary only 
in sulfation pattern, or uronic acid configuration) combined with the highly anionic nature of the 
GAG oligosaccharides means that further separation of individual components is most frequently 
achieved using strong anion-exchange HPLC (SAX-HPLC, Figure 3);
40
 ion-pair reverse phase 
HPLC (IP-RP-HPLC);
41,42
 capillary electrophoresis (CE);
43
 or polyacrylamide gel electrophoresis 
(PAGE).
44
 
 
 
Figure 3. Semi preparative SAX-HPLC of the dp4 fraction of enzymatically digested bovine heparin 
eluted using a 60 min linear gradient from 0 to 1 M sodium chloride (pH 3.5). Peaks I-V represent the 
following species: I: -UA(2S)-(14)--GlcNS(6S)-(14)--IdoA(2S)-(14)-GlcNS(6S); II: -
UA(2S)-(14)--GlcNS(6S)-(14)--GlcA-(14)-GlcNS(6S); III: -UA(2S)-(14)--
GlcNS(6S)-(14)--IdoA(2S)-(14)-GlcNS; IV: -UA(2S)-(14)--GlcNS-(14)--GlcA-
(14)-GlcNS(6S); V: -UA(2S)-(14)--GlcNS-(14)--IdoA(2S)-(14)-GlcNS. 
Page 8 of 41 
The individual saccharide composition and sequence of any particular fraction may then be 
determined by disaccharide analysis,
41,45
 HPLC- or PAGE- based sequencing, or by using mass 
spectrometric-,
46
 or NMR-based,
47
 methods. 
 
2.2 Total chemical or chemoenzymatic synthesis of GAG oligosaccharides 
Recent advances in oligosaccharide synthesis
48
 have rendered the preparation of native GAG 
oligosaccharides (rather than simplified GAG-mimetics) through total chemical synthesis more 
attractive. Total synthesis offers the potential for the generation of GAG oligosaccharides with 
defined sulfation patterns,
49
 on a larger scale than is readily achieved through the controlled 
degradation of native material. The synthetic anticoagulant, antithrombin-binding pentasaccharide, 
fondaparinux,
50
 based upon the native heparin sequence, has recently been marketed worldwide under 
the trade name Arixtra® (Figure 3). Early synthetic endeavours have been reviewed elsewhere,
51
 but 
notable recent achievements in this area include: an efficient one-pot strategy for the synthesis of 
heparin and HS oligosaccharides, in which the formation of uronic acids is achieved by selective 
oxidation of the C-6 hydroxyl group after oligosaccharide synthesis;
52
 the synthesis of sulfated 
heparin-like oligosaccharides on a soluble polymer support;
53
 the synthesis of a HS tetrasaccharide 
with both free and N-acylated amino groups;
54
 the assembly of well-defined CS oligosaccharides 
using convergent synthetic approaches;
55,56
 and the synthesis of microarrays of synthetic heparin 
oligosaccharides of chain length dp2-dp6, using automated solid phase synthesis.
57
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Figure 4. Arixtra®, a synthetic antithrombin-binding pentasaccharide. 
 
One of the principal advantages of a total chemical synthetic approach is that a number of 
activating/reactive groups may be readily introduced to the developing oligosaccharide to allow 
site-specific attachment to functional tags. This is exemplified by the terminal pentenyl glycoside 
which is generated on release of an oligosaccharide from the solid support in Seeberger's 
Page 9 of 41 
automated synthesis protocol. This is readily converted to an amine-functionalised GAG 
oligosaccharide (Scheme 5) appropriate for immobilisation on amine-reactive CodeLink slides.
58
 
Microarrays displaying a small library of synthetic heparin oligosaccharides generated using this 
technology have recently been used to profile heparin-chemokine interactions.
59 
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Scheme 5. Pentenyl glycoside conversion to an amine-functionalised GAG oligosaccharide. 
 
2.3 Chemical and enzymatic modification of GAG precursors 
Despite notable successes in chemical and chemoenzymatic synthesis, longer chain length GAG 
oligosaccharides (>dp6) are still largely inaccessible using current oligosaccharide synthetic 
methodology; hence in vitro systems using biosynthetic enzymes offer a promising alternative 
approach.
60
 Particularly promising is the prospect of using sulfotransferase enzymes for highly 
selective sulfate transfer onto oligosaccharide or polysaccharide precursors.
15,61
 Sulfotransferases 
allow access to sulfate patterns that are difficult to achieve using standard chemical methods, and 
the different isoforms of each transferase (e.g. 6-OST-1 and 6-OST-2a) confer exquisite substrate 
selectivity. This approach is exemplified by the work of Liu et al.; starting from heparosan, a 
capsular polysaccharide of the E. coli K5 strain which is the non-sulfated and unepimerised 
equivalent of heparin/HS, an enzyme-based combinatorial approach to the 
synthesis of a polysaccharide library with different sulfation patterns was developed (Scheme 
6).
62
 The principal drawback of this approach for biophysical, and more detailed biological 
structure-activity studies is that it has not yet been developed to a position where the 
constitutional homogeneity of the resultant synthetic polysaccharides can be guaranteed.  
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In another outstanding example of the use of an enzyme-based modification approach to 
functional GAG oligosaccharide synthesis, the antithrombin-binding pentasaccharide of 
heparin/HS was synthesised in just 6 steps from heparosan (Scheme 7).
63
 This was achieved using 
the enzymes N-deacetylase-N-sulfotransferase (which effects the dual transformation of the 
hexosamine residues from GlcNAc to GlcNS); heparinase III (chain degradation followed by 
isolation of the dp6 fraction); epimerase and 2-OST-1 (GlcA to IdoA interconversion and 2-O-
sulfation of IdoA); 6-OST-1 and 6-OST-2a (glucosamine-6-O-sulfate formation); 4,5-
glycuronidase (to remove the non-reducing terminal UA and generate the pentasaccharide); and 
3-OST-1 (to effect the final 3-O-glucosamine sulfation).  
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Scheme 7. Antithrombin-binding pentasaccharide synthesis by enzymatic modification of heparosan. 
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Chemical processing of the sulfated backbone of GAGs may be achieved in a number of ways,
64
 
but has been most comprehensively studied for heparin. N-desulfation of the pyridinium salt of 
heparin is highly efficient,
65
 and is usually followed by N-acetylation to protect the highly 
reactive amino groups which result.
66
 A straightforward 2-O-desulfation protocol for heparin 
described by Ishihara et al. is also highly efficient and selective.
67
 The 6-O-desulfation of the 
glucosamine residues, leaving the 2-O-sulfation of IdoA intact is the least selective process.
68
 
Under all conditions studied this reaction is accompanied by partial loss of the highly labile 
sulfamido group; however, this may be readily reversed through specific N-resulfation (Scheme 
8).
69,70
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Scheme 8. Specific desulfation reactions of heparin. 
 
3. Chemical Functionalisation 
General methods for the introduction of structural motifs along the oligosaccharide chain of 
heparin structures (e.g. N- and O-acylation, sulfate substitution, carboxylate ester and amide 
formation) have been comprehensively reviewed.
71
 This section therefore focuses more 
specifically on methodology appropriate for the selective introduction of functional labels at 
either the reducing end (Section 3.1) or non-reducing end (Section 3.2) of the GAG 
oligosaccharide, and how these methods are most appropriately combined with the different 
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procedures for GAG oligosaccharide sample preparation.  
3.1 Reducing end functionalisation 
Most GAG oligosaccharide structures possess a reducing terminus with a uniquely reactive 
anomeric centre which may be modified in a number of different ways in common with other 
carbohydrates.
72
 (GAG oligosaccharides produced by chemical cleavage employing nitrous acid 
have a modified reducing terminus, as discussed in Section 2.1.1, which is also highly reactive.) 
For this reason reducing end functionalisation has been widely exploited, for example for the 
attachment of fluorophores to GAG oligosaccharides to aid disaccharide analysis,
41,45
 and 
purification,
73
 and to enable binding affinity studies by gel mobility shift assays.
74
 However, not 
all methods developed for oligosaccharide functionalisation at the reducing end are applicable to 
GAG oligosaccharides and care must be taken to ensure that reaction conditions do not give rise 
to undue structural modifications of the GAG oligosaccharide under study.
75,76
 Thus for example, 
it has been shown that under mildly basic conditions a terminal GlcNS(6S) residue of GAG 
oligosaccharides may be transformed through C2-epimerisation into the corresponding 
ManNS(6S).
75
 In addition the polyanionic nature of GAG oligosaccharides limits options for their 
functionalisation, as sodium salts of heparin are only soluble in water and aqueous buffer 
systems, or water combined with aqueous-miscible solvents such as formamide. Pyridinium or 
ammonium salt forms of GAG oligosaccharides have been shown to have a greater range of 
solubility, and reactions have been demonstrated in DMF, DMSO and even CH2Cl2.
71 
 
3.1.1 Glycosylamine formation and amine derivatisation 
Kochetkov amination,
77
 i.e. the formation of a glycosylamine from a glycoside through treatment 
with an ammonia source, may be achieved under a number of different reaction conditions in 
complex oligosaccharides.
78
 This versatile method has underpinned the preparation of numerous 
neoglycoconjugates since the resultant terminal glycosylamine provides a convenient site for 
chemoselective conjugation and modification.
72
 Typical reaction conditions for the Kochetkov 
reaction involve mild heating (~40 °C) of the oligosaccharide with an ammonia source [e.g. 
NH3(aq.)/NH4HCO3,
79
 NH4CO2NH2,
80
 NH4HCO3,
81
 or (NH4)2CO3
82
] for an extended reaction 
period (>16 h). The use of organic solvents such as methanol, or DMSO can lead to higher yields 
of the unstable glycosylamine products. However, the use of a large excess of the ammonia 
source (5-20 equivalents) means that this reaction is mostly confined to comparatively small 
sample sizes (10-100 mg),
 
and volatile ammonium salts are preferred since they may be removed 
at the end of the reaction by lyophilisation, or by heating in methanol (~70 °C). Nonetheless, 
recent advances such as the application of microwave technology to reduce reaction times to ~90 
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min, suggest that there is still considerable potential for application of the Kochetkov reaction in 
glycobiology.
83,84
  
Since the glycosylamine is predominantly isolated as its ring-closed-anomer, rather than the 
corresponding open chain imine, the structural information associated with this ring is preserved 
rendering this an attractive method for the functionalisation of GAG oligosaccharides (Scheme 
9).
81
 Typically, the only side-product formed in a Kochetkov amination is the diglycosylamine;
82
 
production of which is minimised at lower reaction temperatures (<40 °C).
84
 (It is noteworthy that 
a dilute solution of ammonium bicarbonate is frequently used as a carrier for GAG 
oligosaccharides, demonstrating that they are stable to these conditions for short contact 
periods.)
85
 However, there is as yet only one report of the successful application of the Kochetkov 
reaction to sulfated monosaccharides such as those found in GAG oligosaccharides.
82
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Scheme 9. Kochetkov amination of GlcNAc(6S). 
 
Whilst glycosylamines can be relatively easily obtained they are very labile in slightly acidic or 
neutral aqueous media; thus once formed they are typically acylated to confer additional 
stability.
81
 The reaction of purified complex oligosaccharides with ammonium bicarbonate 
followed by acylation with fluorophores such as dansyl chloride or carboxyfluorescein has been 
shown to be an effective means of derivatisation, although reaction yields and anomeric ratios 
have been shown to be somewhat dependent on the steric bulk of the acylating agent.
81
 However, 
reaction with chloroacetic anhydride followed by ammonolysis of the resultant chloroacetamido 
group (Scheme 10), has been shown to give the -anomeric N-glycine derivatives with high 
selectivity.
81
 More recently, coupling of glycosylamines with FmocAsp(OH)-O
t
Bu in the 
presence of HOBt/HBTU, and subsequent acidic deprotection has been shown to give the 
corresponding Fmoc-protected glycosylamino acids,
86
 and the preparation of an activated ester 
intermediate of the spin label 4-carboxy-TEMPO through treatment with HODhbt/DCC has 
allowed reaction with a LacNAc-derived glycosylamine.
87
 Stabilisation has also been achieved 
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through reaction of the glycosylamine with 2-iminothiolane hydrochloride to generate the 
corresponding N-imino glycosylamidine.
83
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Scheme 10. N-acylation of glycosylamines. 
 
Direct formation of functionalised glycosylamines is an alternative procedure to a Kochetkov 
amination / acylation type sequence.
88
 Glycosylamines prepared using this strategy include those 
of 4-aminobenzoic butyl ester (4-ABBE), 4-aminobenzoic acid (4-ABA), and 2-aminopyridine 
(2-AP) as shown in Figure 5.
88,89
 Glycosylamines formed by reaction with 4-ABA have been 
analysed by CE–ESI-MS–MS, where it has been shown that the closed ring structure of the 
glycosyl amine provides more information on the linkage and anomeric conformation than their 
secondary amine counterparts formed by reductive amination (Section 3.1.3).
89
 With nitrous acid 
depolymerised GAG oligosaccharides the exocyclic aldehyde forms a stable Schiff's base with an 
amine.
90 
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Figure 5. (a-c) Glycosylamines formed by the direct reaction of oligosaccharides with 4-ABBE, 4-
ABA, and 2-AP respectively. (d) Schiff's base formed by coupling nitrous acid depolymerised GAGs 
with amines. 
 
3.1.2 Glycosylhydrazide formation 
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Treatment of GAGs with hydrazine (H2NNH2) is routinely used as a means of removing any N-
acyl groups in the polymer chain.
91,92
 However coupling of the reducing sugar terminus of GAG 
oligosaccharides with a hydrazide (H2NNHCOR) affords an acylhydrazone. Hydrazides are 
attractive for coupling reactions with GAGs as they retain their nucleophilicity in acidic aqueous 
media, and the acylhydrazone which is formed is comparatively stable. Equilibration to the 
tautomeric ring-closed glycosylhydrazide is generally favoured, and this exists predominantly as 
its -anomer (typically >90:10 :, Scheme 11).93,94 The acylhydrazone typically has an H-1 
signal in the range 7.5-7.6 ppm in D2O, whereas the -glycosylhydrazide has an H-1 signal of 
4.2-4.3 ppm.
93
 The acylhydrazide group may also show restricted bond rotation about the N-acyl 
bond, resulting in complex NMR spectra for the products of these reactions.
93
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Scheme 11. Glycosylhydrazide formation. 
 
Complex oligosaccharides,
95
 including heparin-derived oligosaccharides,
96
 have been attached 
directly to hydrazide-coated glass slides to form microarrays through a -glycosylhydrazide 
linkage. The reagent 6-(biotinyl)-aminocaproyl hydrazide (BACH) has also been shown to react 
directly with commercial low molecular weight heparins (Figure 6a).
97
 Glycosylhydrazide 
formation is an attractive approach to functionalisation as it is chemoselective, does not require 
the use of coupling reagents, and the native pyranose form of the reducing sugar is retained. 
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Where a functionalised hydrazine is reacted with GAG oligosaccharides terminated by an 
anhydromannose resulting from deaminative cleavage, formation of the glycosylhydrazone is 
favoured.
98
 It has been shown that reaction of intracellular HS degradation products with 2,4-
dintrophenylhydrazine (DNP) forms a hydrazone which may be visualised through 
immunofluorescence using anti-DNP (Figure 6b).
99
 
 
3.1.3 Reductive amination 
A widely-used method for the functionalisation of the reducing end of oligosaccharide chains is 
reductive amination with an appropriate amine to give the corresponding secondary amine.
72-74,100
 
The reductive amination of GAG oligosaccharides typically requires extended reaction times at 
pH 4-5 in the presence of an excess of amine to form the initial imine, which is reduced in situ 
with an excess of sodium cyanoborohydride (NaCNBH3) or sodium triacetoxy-borohydride 
[NaBH(OAc)3]. Where this reaction is carried out on GAG oligosaccharide samples resulting 
from enzymatic or radical depolymerisation, the reductive amination procedure results in the 
linear form of the reducing terminus sugar, with the associated loss of any structural information 
incorporated in this sugar residue (Scheme 12a). These reactions are also applicable to GAG 
oligosaccharides prepared through treatment with nitrous acid, where the five-membered ring 
formed during the cleavage reaction is retained (Scheme 12b).
101
 Although it requires relatively 
harsh conditions, the reductive amination of GAG oligosaccharides has been used for the 
introduction of fluorophores to aid separation
73,102
 GAG-sequencing,
103
 studies of protein-GAG 
interactions,
74
 and mass spectrometric analysis,
46
 and for the immobilisation of GAG 
oligosaccharides on a range of surfaces.
104
 
 
← Figure 6 (a) Glycosylhydrazide 
formation with lyase-cleaved 
heparin using BACH; and (b) 
glycosylhydrazone formation with 
in vivo radical depolymerised 
GAGs using DNP. 
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Scheme 12. Reductive amination: (a) of lyase or radical depolymerised GAGs with 2-aminoacridone 
(AMAC); (b) of nitrous acid depolymerised GAGs with tyramine. 
 
Despite the enhanced nucleophilicity in acidic aqueous media of hydrazides over their amine 
counterparts, the reductive amination of GAG-acylhydrazones is not often used as a means of 
GAG functionalisation, reflecting the comparative stability of the acylhydrazones themselves. 
However, another variant of the reductive amination procedure, reductive oxyamination, has been 
proposed as an alternative. The reaction of N-substituted hydroxylamines and NaCNBH3 to give 
N,N-disubstituted hydroxylamines proceeds selectively and in quantitative yield under mild 
conditions (aqueous solution, pH 6.5, rt) for a range of monosaccharides.
105
 Unfortunately GlcNS, 
which was used as a model for the reducing terminus of enzyme-cleaved GAG oligosaccharides, 
gave a greatly reduced yield (Scheme 13).
105
 Reaction with the isomeric O-substituted 
hydroxylamines results in the formation of E/Z oxime mixtures and proceeds in quantitative yield 
for GlcNS.
105
 In contrast to acylhydrazones these oximes are thought to exist predominantly in 
the ring-opened form, and they are not amenable to reductive amination.
105
 Oxime derivatives 
themselves have been exploited though, and the disaccharide UA(2S)-GlcNS(6S) has been 
immobilised through an oxime linkage in a recent oligosaccharide microarray.
106
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Scheme 13. Reaction of GlcNS with N- and O-substituted hydroxylamines. 
 
3.2 Non-reducing end functionalisation 
To prepare double-labelled substrates for use in structural studies (e.g. determination of changes 
in solution conformation of GAG oligosaccharides with varying sulfation using TR-FRET),
107
 
selective labelling at the non-reducing end is also required. Bacterial lyase-catalysed cleavage of 
GAGs produces oligosaccharides containing a UA at the non-reducing terminus.29 This unique 
feature in the heavily sulfated GAG chain makes an attractive target for selective 
functionalisation. However, only a limited number of approaches to functionalisation of this 
reactive moiety have been reported, as discussed below.  
 
3.2.1 Double bond functionalisation 
Functionalisation of the captodative 4,5 double bond of lyase-cleaved GAG oligosaccharides is 
challenging as it exhibits both acrylic acid and enol ether electronic character.
108
 Oxymercuration, 
of the 4,5 double bond in these unsaturated uronic acids by mercury salts in H2O and the rapid 
glycosidic bond cleavage which ensues, has been used extensively for the selective removal of 
the terminal unsaturated saccharide moiety in lyase-cleaved GAGs since its introduction in 1987 
(Scheme 4).
38
 Surprisingly in this context, trapping of a mercurinium intermediate formed under 
similar conditions [Hg(OAc)2, THF/H2O, 40 °C, 2 h] by thiol modified surfaces has recently been 
reported.
109
 Oxidative functionalisation of the double bond of unsaturated uronic acids through 
dihydroxylation is similarly known to result in cleavage of the non-reducing terminal sugar.
110
 
Notwithstanding this facile degradation pathway, the reaction of variously protected UA’s with 
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N-bromosuccinimide (NBS) in aqueous THF to generate the corresponding bromohydrins 
(Scheme 14) as a mixture of stereoisomers in good yields has been reported.
111
 But perhaps not 
surprisingly, direct application of this methodology to the double bond of lyase-cleaved heparin-
derived GAG-disaccharides results in extensive decomposition, most probably through glycosidic 
bond cleavage.
112
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Scheme 14. Functionalisation of the captodative double bond in a UA. 
 
Other possible means of chemical functionalisation of GAG UA double bonds, such as Michael 
addition to the captodative double bond,
113
 or Heck reaction of this acrylate-like functionality,
114
 
do not appear to have been attempted on these challenging targets.  
 
3.2.2 Carboxylic acid functionalisation 
Reaction of the carboxylic acid functionality to give either an ester or amide provides an 
attractive alternative to double bond functionalisation as GAGs and GAG oligosaccharides are 
compatible with a range of standard coupling reagents/ conditions, and the resultant modified 
GAGs are relatively stable.
71
 The free acid form of heparin reacts rapidly with diazomethane to 
give the uronic acid methyl ester,
115
 whilst the sodium or ammonium salt reacts with an alkyl 
halide (e.g. benzyl chloride) in the presence of a base to give the corresponding ester (Scheme 
15).
116
 Although uronic esters are stable by comparison with the products of double bond 
functionalisation discussed in Section 3.2.1, esterification lowers the pK a of the H-5 of the uronic 
acid, facilitating proton abstraction and subsequent elimination under basic conditions.
71
 As yet 
the selective esterification of the carboxylic acid at the non-reducing terminus, for instance 
through using a bulky alkylating agent, has not been reported.  
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Scheme 15. Ester formation in GAGs. 
 
The range of coupling reagents available for amide bond formation has increased dramatically in 
recent years, and many new water-soluble coupling reagents have been developed opening up 
new opportunities for peptide bond formation.
117
 Of these coupling agents, the water soluble 
carbodiimide 1-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide (EDC or EDAC) has been 
shown to couple a range of hydrazides to the uronic acids of HA, CS and heparin at pH 5.2,
118
 
and also to cross-link HA through its uronic acids via reaction with dendritic hydrazides.
119
 O-
substituted hydroxylamines have also been coupled to the carboxylate groups of HA with EDC at 
pH 4.75.
120 
In contrast, it has been reported that the reaction of the carboxylates of HA with primary amines 
at pH 4.5 gives rise to the O-acyl urea of EDC (which rapidly rearranges under acidic conditions 
to the more stable N-acyl urea), with none of the expected amide coupled product.
121,122
 
Successful coupling to amines requires the use of HOBt in conjunction with EDC at pH 6.8, or 
conversion to an intermediate N-hydroxysulfosuccinimide ester at pH 7.5 (Scheme 16).
123,124
 
Formation of the N-acyl urea has subsequently been used as the basis of hydrogel formulation 
strategies.
124
 EDC has been reported to couple eight different GAG-disaccharides with the 
fluorophore 7-aminonaphthalene-1,3-disulfonic acid (ANDSA);
125
 the derivatised disaccharides 
were then analysed by capillary electrophoresis. 
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Scheme 16. Peptide and N-acyl urea formation reactions of hyalurronan.  
 
The water soluble coupling agent 4-(4,6-dimethoxy[1,3,5]triazin-2-yl)-4-methyl-morpholinium 
chloride (DMT-MM)
126,127
 has also been employed in amide bond formation to GAG 
oligosaccharides, allowing the direct coupling of 4-amino-TEMPO to a heparin-derived GAG-
disaccharide with good conversion (Scheme 17).
128
 
 
R = Ac, O•
O
NaO3SHN
OSO3Na
O
HO
O
HN
O
NaO3SO
HO
N R
O
NaO3SHN
OSO3Na
O
HO
O
O
NaO3SO
HO
ONa
OH
OH
N
NH2
R
DMT-MM
MeOH: H2O
(2:1)
 
Scheme 17. DMT-MM promoted coupling of 4-amino TEMPO and a 4-amino TEMPO analogue to a 
GAG-disaccharide. 
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Overall these carboxylic acid coupling strategies have been shown to be somewhat dependent 
upon the nature of the amine reactive component employed and, in common with all other 
derivatisation strategies for GAG oligosaccharides, require tight control of reaction conditions 
(pH, temperature etc.) to maximise the conversion to the desired product and minimise undesired 
side-reactions including N- and O- desulfation. Although these methods potentially allow reaction 
with all the uronic acids in a GAG oligosaccharide, it is likely that the overall conformational 
structure will confer some selectivity on this functionalisation.
121
 Finally, the inherent stability of 
the amide/acylhydrazide reaction products is highly desirable if they are to be used in subsequent 
studies. 
 
3.2.3 Chemoenzymatic approaches 
A number of recent results suggest that recombinant GAG biosynthetic,
15,129
 and degradative
29
 
enzymes offer exciting possibilities for the selective introduction of functional labels at the non-
reducing end of GAG oligosaccharides. In one example, two heparosan synthases, PmHS1 and 
PmHS2, from Pasteurella multocida have been expressed and purified using maltose-binding 
protein fusion constructs.
130
 PmHS2 has been shown to have the ability in vitro to catalyse the 
incorporation of several unnatural UDP-donor sugar analogues, including substrates with 
actinide-containing uronic acids or longer acyl chain hexosamine derivatives.
130
 This offers the 
exciting prospect that in future GAG oligosaccharide functionalisation might be controlled 
through the systematic introduction of modified UDP sugar donors. 
In another approach, it has been shown that the ovine testicular hyaluronidase (OTH), a 
hydrolase, can catalyse the copolymerisation of differentially functionalised transition state 
analogue monomers (hyalobiuronate oxazolines) in a regio and stereoselective manner, giving 
rise to HA oligosaccharides bearing non-natural N-acyl groups in their glucosamine residues 
(Scheme 18).
131
 By varying the comonomer feed ratio it was found to be possible to control the 
overall composition of the N-acyl groups. An enhanced control of this process might allow site-
selective introduction of functionalised monomers to the GAG oligosaccharide. 
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Scheme 18. Proposed mechanism for OTH-catalysed polymerisation of hyalobiuronate oxazolines. 
 
4. Applications 
Reductive amination has found widespread use for the introduction of fluorescent and radioactive  
labels to the reducing end of GAG oligosaccharides over the past 30 years (Section 3.1.3);
72-74,102-
104
 these methods have been used to study a wide range of medical conditions related to GAG 
biosynthesis and processing. But in order to gain a deeper understanding of both normal and 
diseased states a detailed assessment of GAG structure and GAG-protein interactions at a 
molecular level is required. Some recent developments in the assessment of GAG-protein 
interactions using traditional and glycomics
13
 based approaches (Section 4.1), and solution phase 
structural studies of GAGs and GAG-protein interactions (Section 4.2), are highlighted. 
 
4.1 Assessment of protein GAG oligosaccharide interactions 
Negatively charged GAGs are very well suited for electrophoretic experiments. Their migration 
in a polyacrylamide or agarose gel, detected by a gel mobility shift assay (GMSA), is retarded 
upon binding to a protein.
74
 Typically a fluorophore is attached to the GAG oligosaccharide via 
reductive amination to aid visualisation of the gel. GMSA may be used to deduce a minimum 
binding size of GAG oligosaccharide; to study the effects of GAG-sulfation patterns on binding; 
and to reveal differences in relative affinity of GAG oligosaccharides to different allotypes of the 
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same protein. In a recent study the assessment of protein binding of heparin oligosaccharides 
(dp2-12) using GMSA has demonstrated that a glycosaminoglycan and protein recognition site in 
factor H module 7 (fH~7) is perturbed by an age-related macular degeneration-linked single 
nucleotide polymorphism (Figure 7).
132 
 
 
Figure 7. GMSA data for His402 and Tyr402 allotypes of fH~7 with AMAC-labelled defined length 
heparin oligosaccharides (dp2-12). A 4-fold molar excess of fH~7 was added to 0.5 g of AMAC-
labelled oligosaccharide. The His402 is a weaker binder requiring a tetrasaccharide to register 
binding. 
 
A number of techniques have been used to immobilise GAG oligosaccharides to surfaces so that 
these surface-bound GAGs may be used to provide a more quantitative assessment of protein-
binding.
133,134
 Approaches which control the orientation of the GAG oligosaccharide through 
attachment at the reducing end (rather than through a non-specific charge-charge immobilisation 
such as found with GAG oligosaccharides immobilised on a polylysine coated slide
135
) are 
attractive because they effectively mimic cell surface presentation of the GAG-motif, and they 
maximise GAG flexibility and accessibility. Modern surface technologies also allow for the use 
of very small quantities of the GAG oligosaccharide under investigation, as well as the 
determination of very weak binding affinities. 
One approach to surface immobilisation is through biotinylation of the reducing end of GAG 
oligosaccharides which may be readily achieved using hydrazide derivatives of biotin (often with 
the inclusion of long-chain linkers between the biotin and hydrazide functionalities that further 
elevate the GAG oligosaccharide above the surface), to form the corresponding biotinyl 
acylhydrazone (c.f. Section 3.1.2). These biotinylated GAGs have been immobilised on 
streptavidin-coated surfaces and used in optical biosensor assays to determine binding 
characteristics of heparin-derived GAG oligosaccharides with hepatocyte growth factor / scatter 
factor (HGF/SF);
136
 with fibroblast growth factor 2 (FGF2);
137
 with glycosylated and 
deglycosylated FGFR;
138
 and with cyclophilin B (CypB).
139
 Lipid tags have also been used as an 
alternative to biotin for the immobilisation of GAG oligosaccharides (Scheme 8).
140 
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Scheme 19. Non-covalent attachment methods used for immobilisation of GAG oligosaccharides: (a) 
charge-charge interactions; (b) streptavidin-biotin interaction (Kd = 10 
-15
); (c) neoglycolipid 
formation and assembly.  
F = fluorophore, B = biotin, L = lipid. 
 
One problem with a non-covalent surface attachment is that it generally requires purification of 
the GAG oligosaccharide (e.g. from unreacted biotin) prior to surface immobilisation; thus 
techniques which offer direct immobilisation of an unfunctionalised sugar to the surface can be 
an attractive alternative, since excess GAG oligosaccharides can simply be washed off the surface 
prior to the bioassay. Microtiter plates, such as those used in ELISA-type assays, coated with 
methyl vinyl ether–maleic anhydride copolymer (MMAC) and modified with adipic dihydrazide 
have been shown to give a surface which reacts directly with the reducing terminus of GAG 
oligosaccharides under reductive amination conditions (Scheme 9).
141
 Reduction of the 
acylhydrazone is not a prerequisite for stability however, as it has also been shown that nitrous 
acid or lyase depolymerised GAG oligosaccharides immobilised through an equivalent adipic 
dihydrazide linker to self assembled monolayers on gold surfaces were stable to storage for 
several weeks when stored at 4 °C in a sealed container.
96
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Scheme 20. Covalent attachment methods for the immobilisation of GAG-oliogsaccharides: (a) 
acylhydrazone formation (lyase depolymerised GAG); (b) Schiff's base formation (nitrous acid 
depolymerised GAG). 
 
Another direct attachment method which has found use in the immobilisation of GAG 
oligosaccharides is Schiff's base formation between the reducing terminus aldohexose or 
anhydromannose and amine-coated slides (Scheme 9). Nitrous acid depolymerised heparin-
derived oligosaccharides (dp8-10) were fractionated into zero, low and high affiinity fractions on 
an antithrombin affinity column and then were printed on -aminosilane-coated glass slides.90 
GAG oligosaccharides displayed in this way maintained their relative antithrombin binding 
affinity. Printing of the GAG oligosaccharide to the -aminosilane coated slide as a solution in 
formamide, and then microwave heating of the slide has been proposed as an effective means of 
accelerating Schiff's base formation.
142
 
 
4.2 Solution phase structural studies 
X-ray crystal structures of GAG-protein complexes often display multiple binding sites, not all of 
which may be valid. For example, crystal structures of heparin-NK1 complexes show two modes 
of binding, the second of which is observed in only one of the two crystal forms and is probably 
the result of crystal packing.
143
 One way to validate these binding sites is by the detailed study of 
GAG-protein interactions in solution by NMR. However, weak binding and large GAG-protein 
proton-proton distances are two major reasons why intermolecular NOEs fail to provide the high 
quality data needed for such NMR structure determination. Chemical shift perturbation analysis 
of 
1
H-
15
N HSQC spectra is therefore a method of choice for delineation of GAG binding sites in 
protein-GAG complexes.
132,144,145
 However, this method provides qualitative information, which 
at best can be used to model the GAG-protein complexes. More detailed information on the 
solution conformation of GAG-protein complexes may be obtained through site-specific 
incorporation of spin labels into the oligosaccharide. The paramagnetic relaxation enhancements 
(PREs) of nuclei, induced by the presence of spin-labels, is well established in the NMR structure 
determination of biomolecules.
146
 But there are only a few examples where a TEMPO-labelled 
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carbohydrate has been used in the application of this methodology to the study of carbohydrate-
protein complexes;
147
 and none of these have been GAG oligosaccharide derivatives. 
A TEMPO-labelled fully sulfated heparin-derived disaccharide (Scheme 17) has been used to 
study the interactions of factor H, a crucial regulator of the alternative pathway of complement, 
with heparin.
132
 The PREs of carbohydrate protons agreed well with the expected values based on 
an AMBER model of this molecule (Figure 8).
128
 This indicates the formation of a rigid peptide 
bond between the 4-amino TEMPO and the COOH group of the terminal modified UA. Such a 
well defined position of the electron radical is a distinct advantage for the interpretation of PRE 
data.  
 
 
Figure 8. Solution conformation of the TEMPO-labelled disaccharide 
TEMPO(4NH2)UA(2S)GlcNS(6S). Selected nitroxy oxygen-proton distances are given in 
Angstroms. 
 
The use of PREs in the assessment of GAG-protein complexes is exemplified by the titration of 
increasing amounts of this TEMPO-labelled heparin disaccharide into the protein, factor H 
module 7 (fH~7). Measurement of the 
1
H relaxation times of NH protons which are significantly 
affected by titration (Figure 9) allows a qualitative assessment of the binding site(s) associated 
with this process, and indicates that at least two GAG binding sites are present in fH~7.
148
 It is 
anticipated that a quantitative interpretation of PREs will reveal more detailed information on 
these binding modes.  
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Figure 9. Surface plot of factor H~7 highlighting residues whose NH protons show largest PREs (in 
decreasing order from red > blue > green > magenta), indicating the existence of more than one GAG-
binding site on this protein. 
 
The use of paramagnetic species in the investigation of GAGs is not limited to the study of 
protein-GAG complexes; they also have great potential for the elucidation of the conformation of 
free oligosaccharides. 
Solution phase interactions have also been extensively studied in biological systems using 
Fluorescence Resonance Energy Transfer (FRET). FRET generates changes in fluorescence 
intensity sensitive to molecular conformation, association and separation, and is widely applied to 
reveal spatial proximity in imaging assays.
149
 Time-resolved FRET (TR-FRET) measured on the 
nanosecond timescale, can detect short-lived conformational states and quantitatively determine 
intermolecular distances on the nanometre scale.
107
 TR-FRET has been used extensively to 
determine distances between amino acids and nucleic acids. Despite the obvious potential of the 
technique, FRET and TR-FRET have not been applied to the study of the solution phase 
conformation of GAG oligosaccharides, or the investigation of solution phase GAG-protein 
interactions.
150
 This is largely because the installation of two fluorophores into a GAG 
oligosaccharide is more difficult than with proteins or nucleic acids, due to a paucity of 
methodology for functionalisation of the non-reducing end.  
In an isolated example of TR-FRET applied to GAG-proteoglycans the acceptor fluorophore is 
conjugated to the protein core through biotinylation and interaction of the biotin with streptavidin 
labelled with a cross-linked phycobilliprotein pigment (XL665).
151
 The donor fluorophore is 
attached to the HS chain through reductive amination of a europium cryptate diamine derivative 
onto a bisaldehyde generated by periodate cleavage of the oligosaccharide chain (Scheme 21). 
This rather non-selectively generated probe may be used in TR-FRET analysis of heparanase 
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activity; although as yet the assay does not give a linear correlation between the reduction in 
signal and degradation of the substrate. This non-linearity is most likely to be due to the 
structural modifications introduced to the HS oligosaccharide chain as a result of the oxidative 
cleavage used to generate sites suitable for the introduction of the europium FRET donor, and 
highlights the need for further developments in the selective conjugation of the non-reducing end 
of GAGs. 
 
XLSAXL
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n
n
n
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Scheme 21. A TR-FRET assay for heparanase activity; B = biotin, SA = streptavidin, XL = XL665, 
Eu = europium cryptate diamine. 
 
5. Conclusions 
If appropriate chemical/enzymatic sample preparation techniques are combined with the use of 
modern coupling reagents and methodologies, a wide array of selectively functionalised GAG 
oligosaccharides could result. These new probes will allow many aspects of GAG-protein 
interactions to be explored, using a range of biophysical techniques, in a manner that has not been 
possible to date. New areas are anticipated to include the use of fluorophores to allow TR-FRET 
and paramagnetic tags for NMR-based studies of GAG oligosaccharide solution conformation; 
NMR spin labels to determine the footprint of GAG oligosaccharides on bound proteins; and the 
exploitation of functionalised GAG oligosaccharide microarrays in glycomics applications. 
Whilst some progress has been made in this area as outlined in this review, it is clear that there is 
still considerable potential for further developments in this field. 
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Notes and references 
‡ This may be achieved in an orthogonal fashion for N-sulfated and free amino sugars: at pH 1.5 
nitrosation of the weakly basic nitrogen of N-sulfated sugars is achieved, most probably by 
H2ONO
+
; at pH 4.0 free amino sugars (which are unreactive at low pH due to protonation) react 
with the predominant species O2NNO, whilst N-sulfated sugars are unreactive.
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